Global Human Gene Sequencing Market Report 2021: A Crowded, Growing Global Market with Complicated Packaging and Pricing is Emerging with Unlimited Growth Opportunities
26 avr. 2021 05h28 HE
|
Research and Markets
Dublin, April 26, 2021 (GLOBE NEWSWIRE) -- The "Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct to...
Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting
08 avr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity and Ionis Pharmaceuticals Enter into Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies
06 avr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, April 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
Progenity Provides Corporate Updates and Reports Fourth Quarter and Full-Year 2020 Financial Results
18 mars 2021 16h05 HE
|
Progenity, Inc.
Reports approximately 82,000 tests in the fourth quarter of 2020 Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M...
Progenity to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
12 mars 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, March 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces $25 Million Private Placement
23 févr. 2021 07h45 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
17 févr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing...
SMFM Conference and Publications Highlight the Challenges and Complexities of Diagnosing and Managing Preeclampsia
12 févr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity to Participate in Two Upcoming Investor Conferences
10 févr. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Reaches Two Million Test Milestone
20 janv. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...